GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuo Therapeutics Inc (OTCPK:AURX) » Definitions » Price-to-Owner-Earnings

Nuo Therapeutics (Nuo Therapeutics) Price-to-Owner-Earnings : (As of May. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Nuo Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-27), Nuo Therapeutics's share price is $0.78. Nuo Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Nuo Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


AURX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.14
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-27), Nuo Therapeutics's share price is $0.78. Nuo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.08. Therefore, Nuo Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-27), Nuo Therapeutics's share price is $0.78. Nuo Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.08. Therefore, Nuo Therapeutics's PE Ratio without NRI for today is At Loss.


Nuo Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Nuo Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuo Therapeutics Price-to-Owner-Earnings Chart

Nuo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nuo Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nuo Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Nuo Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuo Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Nuo Therapeutics's Price-to-Owner-Earnings falls into.



Nuo Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Nuo Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.78/-0.07
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nuo Therapeutics  (OTCPK:AURX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Nuo Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Nuo Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuo Therapeutics (Nuo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8285 El Rio, Suite 190, Houston, TX, USA, 77054
Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company's commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The company derives revenues from the sale of the Aurix product to customers consisting of primarily hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The Aurix product became commercially available for sale in current financial year.
Executives
Charles E Sheedy 10 percent owner TWO HOUSTON CENTER, SUITE 2907, HOUSTON TX 77010
David Emerson Jorden director, officer: CEO, CFO 2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381
Lawrence Atinsky director 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
C Eric Winzer director
Paul Mintz director C/O NUO THERAPEUTICS INC., 207A PERRY PARKWAY, SUITE 1, GAITHERSBURG MD 20877
Peter Clausen officer: CSO 11204 JEFFRO COURT, IJAMSVILLE MD 21754
Scott M. Pittman director 3683 JOHN NASH BLVD., BLUEFIELD WV 24701
Boyalife Investment Fund I, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Dean Tozer officer: CHIEF COMMERCIAL OFFICER C/O ADVANCED BIOHEALING, INC., 36 CHURCH LANE, WESTPORT CT 06880
Steven A Shallcross officer: SEE REMARKS C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Aldagen Holdings, Llc 10 percent owner, other: May be part of a 13(d) group C/O THOMAS A. ALLEN, ESQ., 4101 LAKE BOONE TRAIL, STE 300, RALEIGH NC 27607
Kathryne Carr 10 percent owner, other: May be part of a 13(d) group 315 OLD IVY WAY, SUITE 101, CHARLOTTESVILLE VA 22903
William W Brooke 10 percent owner, other: May be part of a 13(d) group 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Guercio Joseph Del director C/O CLARK INVESTMENTS, 7500 OLD GEORGETOWN ROAD, SUITE 620, BETHESDA MD 20814
B. Jefferson Clark 10 percent owner, other: May be part of a 13(d) group C/O ALDAGEN, INC., 2810 MERDIAN PARKWAY, SUITE 148, DURHAM NC 27713